Potential Therapeutic Targets for CAVD: Recognition of Key Genes in Calcific Aortic Valve Disease with the Integration of Bioinformatic Analysis1
Without sufficient knowledge about the molecular principles and effective pharmaceutical treatment, calcific aortic valve disease (CAVD) remains highly prevalent, accounting for 2% to 7% of primary causes of aortic stenosis aged 65 years or older worldwide. Through an investigation using the microarray datasets of calcific aortic valves and normal aortic valves, a total of 179 differentially expressed genes and 10 hub genes were identified. With the findings showing that these genes and pathways are mostly enriched in inflammatory and immune responses, potential therapeutic targets for CAVD might be discovered. The identification of CCR1, which is used to treat rheumatoid arthritis and shares common underlying mechanisms with CAVD, might remarkably promise the pathogenesis of CAVD.
References
1. Teng P, et al. Medicine. 2020;99(29):e21286.
